- Glycomine’s $115M series C to fund genetic disorder ph. 2 plans Fierce Biotech
- Glycomine raises $115M to see if it can treat rare glycosylation disorder Endpoints Current-News-Report
- Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG Yahoo Finance
- Glycomine gears up for potentially pivotal rare disease study with fresh $115M FirstWord Pharma
- Glycomine Gets $115M Series C for Rare Disease, Aims for Phase II Launch Mid-Year BioSpace
